Zheng Shu, M.D.

Position:Scientific Director of Cancer Institute

Department:Cancer Institute

Medical School:Zhejiang University School of Medicine, China

Academic Rank:Professor, Chief Physician

Clinical / Research Interests

Cancer diagnosis and individualized comprehensive treatment.

Professional Highlights

State Scientific and Technological Progress Award, Second Prize

State Scientific and Technological Progress Award, Third Prize

Scientific and Technological Award of Ministry of Education, First Prize

Zhejiang Scientific and Technological Progress Award, First Prize

Professional Appointments

Fellow, America College of Surgeon

Visiting Professor, Rutgers University, 2004-2005

K.P. Chao Visiting Professor, Chinese University of Hong Kong, 2005

Education Experience

Research Summary

Dr. Zheng established the model of mass health screening for colorectal cancer in China, which has been proved to be effecitve among large population. According to the population-based cancer registry in Haining county, age-adjusted incidence and mortality from rectal cancer decreased by 41% and 29%, respectively, from 1977-1981 to 1992-1996. Observed cumulative 20-year rectal cancer incidence was 31% lower than expected in the screened group; mortality due to rectal cancer was 18% lower than expected in the screened group. It was be proved that mass screening and following with endoscopy and polypectomy can reduce incidence and mortality of rectal cancer among general population in China.


Hu W, Yang Y, Qi L, Chen J, Ge W, Zheng S. Subtyping of microsatellite instability-high colorectal cancer. Cell Commun Signal. 2019 Jul 22;17(1):79.

Weng X, Chen W, Hu W, Xu K, Qi L, Chen J, Lu D, Shao Y, Zheng X, Ye C, Zheng S. PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition. Cell Death Dis. 2019 Apr 30;10(5):352. 

Ge W, Cai W, Bai R, Hu W, Wu D, Zheng S, Hu H. A novel 4-gene prognostic signature for hypermutated colorectal cancer. Cancer Manag Res. 2019 Mar 4;11:1985-1996.

Cai SR, Huang YQ, Zhang SZ, Li QR, Ma XY, Zheng S. Effects of subitems in the colorectal cancer screening protocol on the Chinese colorectal cancer screening program: an analysis based on natural community screening results. BMC Cancer. 2019 Jan 10;19(1):47. 

Hu W, Yang Y, Ge W, Zheng S. Deciphering molecular properties of hypermutated gastrointestinal cancer. J Cell Mol Med. 2019 Jan;23(1):370-379. 

Hu W, Yang Y, Qi L, Chen J, Ge W, Zheng S. Subtyping of microsatellite instability-high colorectal cancer. Cell Commun Signal. 2019 Jul 22;17(1):79.

Mao L, Guo C, Zheng S. Elevated urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine and serum uric acid are associated with progression and are prognostic factors of colorectal cancer. Onco Targets Ther. 2018 Sep 17;11:5895-5902.

Shao Y, Chen T, Zheng X, Yang S, Xu K, Chen X, Xu F, Wang L, Shen Y, Wang T, Zhang M, Hu W, Ye C, Yu X, Shao J, Zheng S. Colorectal Cancer-derived Small Extracellular Vesicles Establish an Inflammatory Pre-metastatic Niche in Liver Metastasis. Carcinogenesis. 2018 Sep 4. doi: 10.1093/carcin/bgy115.

Yu J, Huang Y, Lin C, Li X, Fang X, Zhong C, Yuan Y, Zheng S. Identification of Kininogen 1 as a Serum Protein Marker of Colorectal Adenoma in Patients with a Family History of Colorectal Cancer. J Cancer. 2018 Mar 8;9(3):540-547. 

Guo C, Xie C, Ding P, Qin G, Mo W, Cao X, Zheng S. Quantification of glycocholic acid in human serum by stable isotope dilution ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:315-319.

Hu W, Yang Y, Li X, Huang M, Xu F, Ge W, Zhang S, Zheng S. Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer. Mol Cancer Res. 2018 Mar;16(3):476-485.

Zhang M, Liang JQ, Zheng S. Expressional activation and functional roles of human endogenous retroviruses in cancers. Rev Med Virol. 2019 Mar;29(2):e2025.

Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S. Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci Rep. 2017 Oct 27;7(1):14265. 

Li X, Hu W, Zhou J, Huang Y, Peng J, Yuan Y, Yu J, Zheng S. CLCA1 suppresses colorectal cancer aggressiveness via inhibition of the Wnt/beta-catenin signaling pathway. Cell Commun Signal. 2017 Oct 3;15(1):38. 

Hu W, Yang Y, Li X, Zheng S. Pan-organ transcriptome variation across 21 cancer types. Oncotarget. 2017 Jan 24;8(4):6809-6818.

Current Program

Research on identification and prevention of high risk groups of colorectal cancer. Funding Source: National Key Research and Development Plan of Major Chronic Non-Communicable Disease Prevention and Control

Find People

Search by Family Name

Find A Department

Search by Departments